MedTrace Logo

Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers

NCT02046551 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-05-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate atomoxetine's effects on the rewarding and reinforcing effects of nicotine in a controlled human laboratory study with 24 otherwise healthy nicotine dependent subjects. It is hypothesized that atomoxetine will attenuate the negative effects of nicotine.

Conditions

  • Nicotine Dependence

Interventions

DRUG

Atomoxetine

DRUG

Placebo

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Albert Arias, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02046551 on ClinicalTrials.gov